NAD+ IV therapy claims vs. what the research actually shows
Quick answer
NAD+ injections and IV infusions are compounded preparations with no FDA-approved indication, and the FDA has issued safety communications about sterility and adverse event risks from these products. Oral NAD+ precursors, particularly nicotinamide riboside and nicotinamide mononucleotide, have demonstrated measurable increases in blood NAD+ levels in human clinical trials, though long-term efficacy data in healthy adults remains limited. The clinical decision between oral and parenteral routes requires evaluation by a licensed provider, particularly given the documented risks associated with compounded injectables.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @timothy.mountcastle actually say?
The core argument here is blunt: NAD injections are not FDA-approved, they come from compounding pharmacies with documented safety concerns, and you can skip the whole thing by just taking vitamin B3 orally. He also takes a side swing at B12 "skinny shots," calling them "garbage" and "false advertising." The plastic surgeon framing gives this some credibility on the regulatory side, though that credential matters less for the metabolic biochemistry he wades into.
His main claims boil down to three things: NAD injections have no FDA approval, oral B3 precursors can raise NAD levels endogenously, and take-home injectable NAD kits are dangerous. He's not entirely wrong, but he's also not telling the complete story.
Does the science back this up?
Partially, and it depends which claim you're checking. On the FDA status, he's correct. NAD+ for injection has no FDA-approved indication, and the FDA has issued alerts about compounded NAD+ products citing sterility concerns and adverse event reports. That part holds up.
The oral B3 argument is where things get messier. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors that have shown measurable increases in blood NAD+ levels in human trials. Elhassan et al. (2019, Cell Reports) demonstrated that oral NR supplementation significantly raised whole-blood NAD+ in healthy older adults. Rajman et al. (2018, Cell Metabolism) reviewed the preclinical and early clinical evidence for NAD precursors broadly. So yes, oral routes work for raising NAD+. But "take some vitamin B3" oversimplifies the precursor landscape considerably. Plain niacin, NR, and NMN are not interchangeable, and the bioavailability differences are real.
What did they get wrong (or right)?
He got the regulatory picture right. NAD injections are compounded, not FDA-approved, and there are legitimate safety questions about sterility and preparation quality. Giving patients take-home injectable NAD kits is a legitimate concern worth raising loudly.
Where he stumbles is conflating all forms of vitamin B3 as equivalent NAD precursors. Saying "just take some vitamin B3" flattens a meaningful biochemical distinction. Nicotinic acid (classic niacin) and nicotinamide have different conversion efficiencies and side effect profiles compared to NR or NMN. The research behind NR and NMN is more specific than plain niacin supplementation for NAD+ repletion. Conze et al. (2019, Scientific Reports) showed NR's safety and pharmacokinetics in detail. The "endogiously" comment, likely meaning endogenously, is a slip but the underlying point about endogenous synthesis is real.
On the B12 "skinny shot" claim, he's largely correct. There is no robust clinical evidence that injectable B12 promotes weight loss in people who are not B12-deficient. That characterization as false advertising is fair.
What should you actually know?
The honest picture is that NAD+ biology is genuinely interesting and the compounded injection market is running well ahead of the evidence. That doesn't mean injections are useless, but it does mean the risk-to-benefit math isn't proven for healthy adults seeking "energy" and "cellular wellness."
If you're considering any form of NAD+ therapy, the things worth knowing are: the oral precursor data is real but mostly short-term and in specific populations; IV and injectable NAD+ lacks controlled trial data showing superiority over oral routes in healthy people; and compounded injectables carry sterility risks that oral supplements simply don't. Yoshino et al. (2021, Science) showed NMN improved muscle insulin sensitivity in postmenopausal women, which is promising but not a green light for everyone.
The take-home injectable concern the creator raises is legitimate and underreported. Patients self-administering compounded injectables without clinical supervision is a real harm vector. On that specific point, he's doing useful public health work.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
NAD+ Peptide Complex access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For NAD+ IV therapy claims vs. what the research actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
NAD+ Peptide Complex is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this nad+ video claims cluster
Best for searchers separating NAD+ longevity marketing from practical metabolic and safety questions.
Claim verdict
The useful answer behind this video
Claim being checked
NAD+ injections and IV infusions are compounded preparations with no FDA-approved indication, and the FDA has issued safety communications about sterility and adverse event risks from these products.
FormBlends verdict
NAD+ injections and IV infusions are compounded preparations with no FDA-approved indication, and the FDA has issued safety communications about sterility and adverse event risks from these products. Oral NAD+ precursors, particularly nicotinamide riboside and nicotinamide mononucleotide, have demonstrated measurable increases in blood NAD+ levels in human clinical trials, though long-term efficacy data in healthy adults remains limited. The clinical decision between oral and parenteral routes requires evaluation by a licensed provider, particularly given the documented risks associated with compounded injectables.
Patient-safe next step
Compare the claim with the NAD+ Peptide Complex guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- NAD+ injections and IV infusions are compounded preparations with no FDA-approved indication, and the FDA has issued safety communications about sterility and adverse event risks from these products. Oral NAD+ precursors, particularly nicotinamide riboside and nicotinamide mononucleotide, have demonstrated measurable increases in blood NAD+ levels in human clinical trials, though long-term efficacy data in healthy adults remains limited. The clinical decision between oral and parenteral routes requires evaluation by a licensed provider, particularly given the documented risks associated with compounded injectables.
- NAD+ for injection has no FDA-approved indication as of 2024, making all injectable NAD+ products compounded preparations subject to variable quality standards.
- The FDA issued a safety alert on compounded NAD+ citing sterility concerns and adverse events including chills and potential infections.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- NAD+ Peptide Complex decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the NAD+ Peptide Complex guide, cost path, safety notes, and provider review before acting.
Review NAD+ Peptide ComplexWhat You'll Learn
- NAD+ for injection has no FDA-approved indication as of 2024, making all injectable NAD+ products compounded preparations subject to variable quality standards.
- The FDA issued a safety alert on compounded NAD+ citing sterility concerns and adverse events including chills and potential infections.
- Elhassan et al. (2019, Cell Reports) confirmed oral nicotinamide riboside raises whole-blood NAD+ in humans, supporting the oral precursor route as evidence-backed.
- Plain niacin, NR, and NMN have different conversion pathways and bioavailability profiles and are not interchangeable despite all being classified as vitamin B3 compounds.
- Yoshino et al. (2021, Science) found NMN improved muscle insulin sensitivity in postmenopausal women, one of the more rigorous human trials to date, though results are population-specific.
- No peer-reviewed clinical trial has demonstrated that injectable or IV NAD+ produces superior outcomes compared to oral precursors in healthy adults seeking general wellness benefits.
- Injectable B12 for weight loss has no clinical evidence base in non-deficient individuals, and marketing it as a fat-loss tool is not supported by the available data.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Mountcastle⭐Plastic Surgeon · TikTok creator
58.1K views on this video
NAD⁺ injections and IV infusions are not FDA-approved for any medical condition. These compounded treatments may support energy, recovery, and cellular wellness but results vary, and research is ongoing. Always consult a licensed provider before treatment. #NADTherapy #IVDrip #WellnessClinic #MountcastleMedSpa #medspa
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Mountcastle⭐Plastic Surgeon, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.